S49 Stock Overview
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Supernus Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$29.80 |
52 Week High | US$35.00 |
52 Week Low | US$21.40 |
Beta | 0.97 |
1 Month Change | 12.03% |
3 Month Change | 12.03% |
1 Year Change | -11.31% |
3 Year Change | 34.23% |
5 Year Change | -8.65% |
Change since IPO | 623.83% |
Recent News & Updates
Recent updates
Shareholder Returns
S49 | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | -7.5% | 4.0% | 2.5% |
1Y | -11.3% | -24.6% | 7.0% |
Return vs Industry: S49 exceeded the German Pharmaceuticals industry which returned -25.9% over the past year.
Return vs Market: S49 underperformed the German Market which returned 7.3% over the past year.
Price Volatility
S49 volatility | |
---|---|
S49 Average Weekly Movement | 5.3% |
Pharmaceuticals Industry Average Movement | 6.3% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: S49 has not had significant price volatility in the past 3 months.
Volatility Over Time: S49's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2005 | 652 | Jack Khattar | https://www.supernus.com |
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company’s commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson’s Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients.
Supernus Pharmaceuticals, Inc. Fundamentals Summary
S49 fundamental statistics | |
---|---|
Market cap | €1.71b |
Earnings (TTM) | €1.22m |
Revenue (TTM) | €561.17m |
1,403x
P/E Ratio3.0x
P/S RatioIs S49 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
S49 income statement (TTM) | |
---|---|
Revenue | US$607.52m |
Cost of Revenue | US$83.78m |
Gross Profit | US$523.74m |
Other Expenses | US$522.43m |
Earnings | US$1.32m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.024 |
Gross Margin | 86.21% |
Net Profit Margin | 0.22% |
Debt/Equity Ratio | 0% |
How did S49 perform over the long term?
See historical performance and comparison